ZE 74 0282
Alternative Names: ZE 74-0282Latest Information Update: 28 Dec 2025
At a glance
- Originator Eilean Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Janus kinase 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myeloproliferative disorders; Polycythaemia vera
- Discontinued Cancer
Most Recent Events
- 17 Dec 2025 Eilean Therapeutics submits an IND application for first-in-human clinical studies of ZE74 0282
- 17 Dec 2025 Eilean Therapeutics plans a first-in-human clinical trial for myeloproliferative disorders and polycythaemia vera (In volunteers) in the first quarter of 2026
- 06 Dec 2025 Pharmacokinetic and pharmacodynamics data from preclinical studies presented at the at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)